228 related articles for article (PubMed ID: 35879722)
1. Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial.
See AW; Bowden P; Wells G; Appu S; Lawrentschuk N; Liodakis P; Pandeli C; Aarons Y; Smyth LML; McKenzie DP
Radiat Oncol; 2022 Jul; 17(1):131. PubMed ID: 35879722
[TBL] [Abstract][Full Text] [Related]
2. The use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial.
Chao M; Lim Joon D; Khoo V; Lawrentschuk N; Ho H; Spencer S; Chan Y; Tan A; Pham T; Sengupta S; McMillan K; Liu M; Koufogiannis G; Cham CW; Foroudi F; Bolton D
World J Urol; 2019 Jun; 37(6):1111-1116. PubMed ID: 30251049
[TBL] [Abstract][Full Text] [Related]
3. Low rectal toxicity after dose escalated IMRT treatment of prostate cancer using an absorbable hydrogel for increasing and maintaining space between the rectum and prostate: results of a multi-institutional phase II trial.
Uhl M; van Triest B; Eble MJ; Weber DC; Herfarth K; De Weese TL
Radiother Oncol; 2013 Feb; 106(2):215-9. PubMed ID: 23333011
[TBL] [Abstract][Full Text] [Related]
4. SABR for High-Risk Prostate Cancer: A Prospective Multilevel MRI-Based Dose Escalation Trial.
Hannan R; Salamekh S; Desai NB; Garant A; Folkert MR; Costa DN; Mannala S; Ahn C; Mohamad O; Laine A; Kim DWN; Dickinson T; Raj GV; Shah RB; Wang J; Jia X; Choy H; Roehrborn CG; Lotan Y; Timmerman RD
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):290-301. PubMed ID: 34774676
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison.
Ogita M; Yamashita H; Nozawa Y; Ozaki S; Sawayanagi S; Ohta T; Nakagawa K
Radiat Oncol; 2021 Jun; 16(1):107. PubMed ID: 34118956
[TBL] [Abstract][Full Text] [Related]
6. Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial.
Uhl M; Herfarth K; Eble MJ; Pinkawa M; van Triest B; Kalisvaart R; Weber DC; Miralbell R; Song DY; DeWeese TL
Radiat Oncol; 2014 Apr; 9():96. PubMed ID: 24758224
[TBL] [Abstract][Full Text] [Related]
7. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy.
Mariados N; Sylvester J; Shah D; Karsh L; Hudes R; Beyer D; Kurtzman S; Bogart J; Hsi RA; Kos M; Ellis R; Logsdon M; Zimberg S; Forsythe K; Zhang H; Soffen E; Francke P; Mantz C; Rossi P; DeWeese T; Hamstra DA; Bosch W; Gay H; Michalski J
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):971-977. PubMed ID: 26054865
[TBL] [Abstract][Full Text] [Related]
8. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
9. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.
Hoffman KE; Voong KR; Pugh TJ; Skinner H; Levy LB; Takiar V; Choi S; Du W; Frank SJ; Johnson J; Kanke J; Kudchadker RJ; Lee AK; Mahmood U; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1074-84. PubMed ID: 24661661
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer.
Eckert F; Alloussi S; Paulsen F; Bamberg M; Zips D; Spillner P; Gani C; Kramer U; Thorwarth D; Schilling D; Müller AC
BMC Cancer; 2013 Jan; 13():27. PubMed ID: 23336502
[TBL] [Abstract][Full Text] [Related]
11. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
12. Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy.
Chao M; Ho H; Chan Y; Tan A; Pham T; Bolton D; Troy A; Temelcos C; Sengupta S; McMillan K; Cham CW; Liu M; Ding W; Subramanian B; Wasiak J; Lim Joon D; Spencer S; Lawrentschuk N
BJU Int; 2018 Sep; 122(3):427-433. PubMed ID: 29520983
[TBL] [Abstract][Full Text] [Related]
13. Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy.
Yeh J; Lehrich B; Tran C; Mesa A; Baghdassarian R; Yoshida J; Torrey R; Gazzaniga M; Weinberg A; Chalfin S; Ravera J; Tokita K
Brachytherapy; 2016; 15(3):283-287. PubMed ID: 26853354
[TBL] [Abstract][Full Text] [Related]
14. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
[TBL] [Abstract][Full Text] [Related]
16. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms.
Boersma LJ; van den Brink M; Bruce AM; Shouman T; Gras L; te Velde A; Lebesque JV
Int J Radiat Oncol Biol Phys; 1998 Apr; 41(1):83-92. PubMed ID: 9588921
[TBL] [Abstract][Full Text] [Related]
17. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis.
Teh BS; Mai WY; Uhl BM; Augspurger ME; Grant WH; Lu HH; Woo SY; Carpenter LS; Chiu JK; Butler EB
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):705-12. PubMed ID: 11172952
[TBL] [Abstract][Full Text] [Related]
18. SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: A systematic review.
Payne HA; Pinkawa M; Peedell C; Bhattacharyya SK; Woodward E; Miller LE
Medicine (Baltimore); 2021 Dec; 100(49):e28111. PubMed ID: 34889268
[TBL] [Abstract][Full Text] [Related]
19. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
20. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
